Drug intelligence / Profile preview

INCB007839 + trastuzumab + vinorelbine

Development stage: Discontinued
Lead developer: Incyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination therapy consisting of INCB007839 (aderbasib), trastuzumab, and vinorelbine. INCB007839 is an orally available inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins, specifically targeting ADAM10 and ADAM17 proteases. It blocks the activation of epidermal growth factor receptor (EGFR) pathways. Trastuzumab is a monoclonal antibody targeting HER2, while vinorelbine is a chemotherapeutic agent. This combination was investigated for the treatment of metastatic HER2-positive breast cancer.

Other names: Aderbasib + trastuzumab + vinorelbine

Targets

TUBB (Tubulin (alpha and beta subunits))ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)ADAM17 (A disintegrin and metalloprotease 17)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on INCB007839 + trastuzumab + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCB007839 + trastuzumab + vinorelbine.

Explore the full profile